As filed with the Securities and Exchange Commission on June 19, 2013
Registration No. 333-
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
PTC Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware |
|
2834 |
|
04-3416587 |
(State or Other Jurisdiction of |
|
(Primary Standard Industrial |
|
(I.R.S. Employer |
Incorporation or Organization) |
|
Classification Code Number) |
|
Identification Number) |
100 Corporate Court
South Plainfield, New Jersey 07080
(908) 222-7000
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrants Principal Executive Offices)
Stuart W. Peltz, Ph.D.
Chief Executive Officer
PTC Therapeutics, Inc.
100 Corporate Court
South Plainfield, New Jersey 07080
(908) 222-7000
(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)
copies to:
David E. Redlick Brian A. Johnson Wilmer Cutler Pickering Hale and 7 World Trade Center, 250 New York, New York 10007 Telephone: (212) 230-8800 Fax: (212) 230-8888 |
|
Mark E. Boulding Executive Vice President and Chief Legal PTC Therapeutics, Inc. 100 Corporate Court South Plainfield, New Jersey 07080 Telephone: (908) 222-7000 Fax: (908) 222-1128 |
|
Richard Truesdell, Jr. Davis Polk & Wardwell LLP 450 Lexington Avenue New York, New York 10017 Telephone: (212) 450-4000 Fax: (212) 701-5800 |
Approximate date of commencement of proposed sale to the public: As soon as practicable after this Registration Statement becomes effective.
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. o
If this Form is filed to register additional securities for an offering pursuant Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. x 333-188657
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer o |
|
Accelerated filer o |
Non-accelerated filer x (Do not check if a smaller reporting company) |
|
Smaller reporting company o |
CALCULATION OF REGISTRATION FEE
Title of each class of securities |
|
Amount to be |
|
Proposed maximum |
|
Proposed maximum |
|
Amount of |
| |||
Common Stock, $0.001 par value per share |
|
1,692,800 shares |
|
$ |
15.00 |
|
$ |
25,392,000 |
|
$ |
3,464 |
|
(1) Includes 220,800 shares which the underwriters have the option to purchase.
(2) Estimated in accordance with Rule 457(a) of the Securities Act of 1933 solely on the basis of $15.00, the Initial Public Offering Price set forth on the cover page of the Registrants Prospectus dated June 19, 2013 relating to its initial public offering pursuant to the Companys Registration Statement on Form S-1 (File No. 333-188657).
EXPLANATORY NOTE AND INCORPORATION BY REFERENCE
This registration statement is being filed with respect to the registration of additional shares of common stock, $0.001 par value per share, of PTC Therapeutics, Inc., a Delaware corporation, pursuant to Rule 462(b) under the Securities Act of 1933, as amended. The contents of the earlier registration statement on Form S-1 (File No. 333-188657), which was declared effective by the Commission on June 19, 2013, are incorporated in this registration statement by reference.
The required opinions and consents are listed on an Exhibit Index attached hereto and filed herewith.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the Borough of South Plainfield, State of New Jersey, on this 19th day of June, 2013.
|
PTC Therapeutics, Inc. | |
|
| |
|
| |
|
By: |
/s/ Stuart W. Peltz, Ph.D. |
|
|
Name: Stuart W. Peltz, Ph.D. |
|
|
Title: Chief Executive Officer |
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
Signature |
|
Title |
|
Date | |
|
|
|
|
| |
/s/ Stuart W. Peltz, Ph.D. |
|
Chief Executive Officer and Director |
|
June 19, 2013 | |
Stuart W. Peltz, Ph.D. |
|
(principal executive officer) |
|
| |
|
|
|
|
| |
/s/ Shane Kovacs |
|
Chief Financial Officer |
|
June 19, 2013 | |
Shane Kovacs |
|
(principal financial and accounting officer) |
|
| |
|
|
|
|
| |
* |
|
Chairman of the Board |
|
June 19, 2013 | |
Michael Schmertzler |
|
|
|
| |
|
|
|
|
| |
* |
|
Director |
|
June 19, 2013 | |
Richard Aldrich |
|
|
|
| |
|
|
|
|
| |
* |
|
Director |
|
June 19, 2013 | |
Axel Bolte |
|
|
|
| |
|
|
|
|
| |
* |
|
Director |
|
June 19, 2013 | |
Allan Jacobson, Ph.D. |
|
|
|
| |
|
|
|
|
| |
* |
|
Director |
|
June 19, 2013 | |
Adam Koppel, M.D., Ph.D. |
|
|
|
| |
|
|
|
|
| |
* |
|
Director |
|
June 19, 2013 | |
Michael Kranda |
|
|
|
| |
|
|
|
|
| |
* |
|
Director |
|
June 19, 2013 | |
Geoffrey McDonough, M.D. |
|
|
|
| |
|
|
|
|
| |
* |
|
Director |
|
June 19, 2013 | |
David P. Southwell |
|
|
|
| |
|
|
|
|
| |
* |
|
Director |
|
June 19, 2013 | |
Jerome B. Zeldis, M.D., Ph.D. |
|
|
|
| |
|
|
|
|
| |
*By: |
/s/ Stuart W. Peltz, Ph.D. |
|
|
|
|
|
Name: Stuart W. Peltz, Ph.D. |
|
|
|
|
|
Title: Attorney-in-Fact |
|
|
|
|
EXHIBIT INDEX
Exhibit No. |
|
Description | |
|
|
|
|
5.1 |
|
|
Opinion of Wilmer Cutler Pickering Hale and Dorr LLP |
23.1 |
|
|
Consent of Ernst & Young LLP, independent registered public accounting firm |
23.2 |
|
|
Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1) |
24.1 |
* |
|
Powers of Attorney |
* Filed as Exhibit 24.1 to the Registrants Registration Statement on Form S-1 (File No. 333-188657) filed with the Securities and Exchange Commission on May 16, 2013.